Synthesis and antitumor activity of the immunoconjugate BR96-Dox

Journal of Controlled Release

Volumn 39, Issue 2-3, 1996, Pages 251-259

  Firestone, R A ^a   Willner, D ^a   Hofstead, S J ^a   King, H D ^a   Kaneko, T ^a,b   Braslawsky, G R ^a,c   Greenfield, R S ^a,d   Trail, P A ^a   Lasch, S J ^a   Henderson, A J ^a   Casazza, A M ^a   Hellstrom I ^a   Hellstrom K E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c BIOGEN   (United States)

^d NONE   (United States)

Author keywords

Acid labile hydrazone; Antibody mediated targeting; Antitumor targeting; Doxorubicin; Endocystosis; Hydrazone; Lysosome

Indexed keywords

ANTIBODY CONJUGATE; BR96 DOX; DOXORUBICIN; MONOCLONAL ANTIBODY BR 96; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER REGRESSION; COLON TUMOR; CONFERENCE PAPER; DRUG SYNTHESIS; ENDOCYTOSIS; LUNG CANCER; LYSOSOME; PRIORITY JOURNAL;

EID: 0029997822     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(95)00160-3     Document Type: Conference Paper

References (17)

1. I. Hellström, P.L. Beaumier and K.E. Hellström, Antitumor effects of L6, an IgG2a antibody reacting with most human carcinomas, Proc. Natl. Acad. Sci. USA 83 (1986) 7059-7063.
2. y-related cell surface antigens, Cancer Res. 50 (1990) 2183-2190.
3. G.R. Braslawsky, K. Kadow, J. Knipe, K. McGoff, M. Edson, T. Kaneko and R.S. Greenfield, Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity, Cancer Immunol. Immunother. 33 (1991) 367-374.
4. R.S. Greenfield, T. Kaneko, A. Daues, M.A. Edson, K.A. Fitzgerald, L. Olech. J.A. Grattan and G.R. Braslawsky, Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker, Cancer Res. 50 (1990) 6600-6607; G.R. Braslawsky, M.A. Edson, W. Pearce, T. Kaneko and R.S. Greenfield, Antitumor activity of adriamycin (hydrazone linked) immunoconjugates compared to free adriamycin and specificity of tumor cell killing, Cancer Res. 50 (1990) 6608-6614.
5. R.S. Greenfield, T. Kaneko, A. Daues, M.A. Edson, K.A. Fitzgerald, L. Olech. J.A. Grattan and G.R. Braslawsky, Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker, Cancer Res. 50 (1990) 6600-6607; G.R. Braslawsky, M.A. Edson, W. Pearce, T. Kaneko and R.S. Greenfield, Antitumor activity of adriamycin (hydrazone linked) immunoconjugates compared to free adriamycin and specificity of tumor cell killing, Cancer Res. 50 (1990) 6608-6614.
6. T. Kaneko, D. Willner, I. Monkovic, J.O. Knipe, G.R. Braslawsky, R.S. Greenfield and D.M. Vyas, New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity, Bioconj. Chem. 2 (1991) 133-141.
7. P.A. Trail, D. Willner, S.J. Lasch, A.J. Henderson, R.S. Greenfield, D. King, M.E. Zoeckler and G.R. Braslawsky, Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models, Cancer Res. 52 (1992) 5693-5700.
8. H.P. Fell, S. Yarnold, I. Hellström, K.E. Hellström and K.R. Folger. Homologous recombination in hybridoma cells: heavy chain chimeric antibody produced by gene targeting, Proc. Natl. Acad. Sci. USA 83 (1989) 8507-8511.
9. D. Willner, P.A. Trail, S.J. Hofstead, H.D. King, S.J. Lasch, G.R. Braslawsky, R.S. Greenfield, T. Kaneko and R.A. Firestone, (6-Maleimidopropyl) hydrazone of doxorubicin -a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconj. Chem. 4 (1993) 521-527.
10. P.A. Trail, D. Willner, S.J. Lasch, A.J. Henderson, S.J. Hofstead, A.M. Casazza, R.A. Firestone, I. Hellström and K. E. Hellström, Science 261 (1993) 212-215.
11. y specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes, Am. J. Pathol. 142 (1993) 607-622.
12. P. Gunewardena and K.B. Cook, 1,4-Dithiothreitol as a reagent for reductive degradation of human J-G globulin, Biochem. J. 99 (1966), 8p.
13. C. Wilmanns, D. Fan, C.A. O'Brian, C.D. Bucana and I. J. Fidler, Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon cancer cells to doxorubicin and 5-fluorouracil, Int. J. Cancer 52 (1992) 98-104.
14. K. Gohji, M. Nakajima, C.P.N. Dinney, D. Fan, S. Pathak, J.J. Killion, A.C. Von Eschenbach and I.J. Fidler, The importance of orthotopic implantation to the isolation and biological characterization of a metastatic human clear cell renal carcinoma in nude mice. Int. J. Oncol. 2 (1993), 23-32.
15. I.J. Fidler, Critical factors in the biology of human cancer metastasis, Cancer Res. 50 ( 1990) 6130-6138; R.M. Hoffman, Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J. Cell. Biochem. 56 (1994) 1-3.
16. I.J. Fidler, Critical factors in the biology of human cancer metastasis, Cancer Res. 50 ( 1990) 6130-6138; R.M. Hoffman, Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J. Cell. Biochem. 56 (1994) 1-3.
17. D. Theodorescu, I. Cornil, C. Sheehan, S. Man and R.S. Kerbel, Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread, Int. J. Cancer 47 (1991) 118-123.